Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The MSI-H And dMMR Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, there has been exceptional growth in the market size of MSI-H and dMMR. This market, valued at $6.15 billion in 2024, is projected to rise to $7.57 billion in 2025, indicating a compound annual growth rate (CAGR) of 23.0%. The significant advancement during the historical timeframe is linked with the escalating rate of colorectal and endometrial cancers, expanded genetic testing, increasing utilisation of MSI tests in clinical settings, surge in awareness of inherited cancer syndromes, and an increased adoption of liquid biopsies.

There is a prediction for a significant surge in the market size of MSI-H and dMMR in the coming years. At a Compound Annual Growth Rate (CAGR) of 22.9%, it is projected to reach a figure of $17.26 billion by 2029. Various factors contribute to this anticipated expansion, including the rising need for customised cancer treatments, evolving uses of next-generation sequencing, increasing expenditure in cancer treatment healthcare, the boost in clinical trials regarding immune checkpoint inhibitors, and supportive regulatory policies for companion diagnostics. Throughout the forecasted period, some notable trends are the incorporation of artificial intelligence into diagnostic procedures, the collab between pharmaceutical and diagnostic companies, the invention of multiplex biomarker panels, advancements in immunotherapy, and the trend towards pan-cancer biomarker testing.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of MSI-H And dMMR Market?

The anticipated growth of the MSI-H and dMMR market is largely driven by the increasing incidence of cancer. This term refers to several diseases having a common trait of unchecked growth and spread of abnormal cells within the body. The key factor behind the increasing cancer prevalence is the aging of populations, as cancer development risk substantially rises with age due to the accumulation of genetic mutations and long-term exposure to various risk factors. To identify tumors with high mutation rates resulting from uncorrected DNA repair errors, MSI-H and dMMR are used in cancer diagnostics. These biomarkers are instrumental in influencing decisions around immunotherapy due to the fact that such tumors likely yield a better response to immune checkpoint inhibitors. They also give insight into prognosis and possible genetic syndromes. As an example, the American Cancer Society revealed that there were an expected 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023, in the United States. Projections for 2024 suggest a rise, with about 2,001,140 new cancer cases and 611,720 deaths projected, indicating a sustained increase in both cancer incidence and mortality rates. Thus, the accelerating prevalence of cancer is fueling the growth of the MSI-H and dMMR market.

Which Key Market Segments Comprise the MSI-H And dMMR Market and Drive Its Revenue Growth?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Which Areas Are Leading Regions in the MSI-H And dMMR Market Expansion Across the Globe?

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theMSI-H And dMMR Market Direction?

Key players in the MSI-H and dMMR market are gearing toward the creation of novel treatments such as combination therapy, with the aim of augmenting treatment effectiveness and bolstering patient prognosis. Combination therapy for MSI-H and dMMR cancers works through the simultaneous application of two or more treatment methods, typically including immunotherapy components like checkpoint inhibitors or adding immunotherapy to chemotherapy, targeted therapy, or radiation. The intention behind this tactic is to boost response to treatment, overcome resistance, and aid in augmenting survival probabilities in patients with tumors demonstrating high microsatellite instability or deficient mismatch repair traits. For instance, Bristol-Myers Squibb Company, a pharmaceutical company based in the US, in April 2025, secured approval from the United States Food and Drug Administration (FDA) for the amalgamation of nivolumab (Opdivo) and ipilimumab (Yervoy), earmarked as an initial treatment strategy for metastatic colorectal cancer (mCRC) with features of either microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This advanced the treatment opportunities for this obstinate category of cancer. The approval stands as a transformative event in the treatment landscape of MSI-H and dMMR cancers as it offers a new, potent treatment alternative which targets multiple routes to augment patient survival and response rates, thereby addressing the previously unfulfilled medical needs of this group of patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

How Is the MSI-H And dMMR Market Conceptually Defined?

MSI-H (microsatellite instability-high) and dMMR (deficient mismatch repair) refer to genetic abnormalities where the DNA repair system fails to correct replication errors, leading to high mutation rates. These markers are commonly found in certain cancers, such as colorectal and endometrial. Tumors with MSI-H and dMMR often respond well to immunotherapy due to their high immunogenicity.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24324

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model